Development of nomograms to predict therapeutic response and prognosis of non-small cell lung cancer patients treated with anti-PD-1 antibody

Yuan, Shuiqiao; Xia, Yan; Shen, Lihong; Ye, Liuqing; Li, Lisha; Chen, Lifen; Xie, Xinyou; Lou, Hongbo; Zhang, Jun

doi:10.1007/s00262-020-02710-9

Cited by 17 publications

(24 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The Cox proportional hazards regression model was used to compare whether the survival distributions differed between the two risk groups. Finally, we compared the current nomogram with Yuan's nomogram (14), which was developed to predict prognosis in NSCLC patients treated with anti−PD−1 antibody, to demonstrate the advantage of the current nomogram to guide treatment decisions for patients treated with ICIs combined with chemotherapy. All statistical analyses were performed using SPSS version 24.0 Statistical Software (SPSS Inc., Chicago, IL, USA) and the R program (version 4.2.0).…”

Section: Discussionmentioning

confidence: 99%

“…Mezquita et al (27) showed that a baseline dNLR >3 was independently associated with PFS in patients with advanced NSCLC treated with PD-1/PD-L1 inhibitors. Additionally, Yuan et al (14) showed that a high dNLR was associated with a poorer OS and developed a nomogram that incorporated dNLR to predict prognosis of NSCLC patients treated with anti−PD−1 antibodies. In our present study, we found that increased dNLR was also correlated with poor outcomes with ICI plus chemotherapy.…”

Section: Discussionmentioning

confidence: 99%

“…Treatment records included the number of treatment lines, immunotherapy combined with chemotherapy regimens, and commencement/progression time of the treatment strategy. NLR = ANC/ALC, dNLR = ANC/(WBC − ANC) as defined previously (14).…”

Section: Data Collectionmentioning

confidence: 99%

“…However, in a subgroup analysis of PFS, a programmed death-ligand 1 tumor proportion score (PD-L1 TPS) <1% was not associated with PFS, which means that the level of PD-L1 expression was not entirely associated with the prognosis. PD-L1 as a predictive biomarker for patients treated with PD-1 inhibitors unfortunately remains complex, with inconsistent data between studies (4,12,14,15). Similarly, there is no association between tissue tumor mutation burden (TMB) and efficacy for pembrolizumab plus chemotherapy or chemotherapy alone based on KEYNOTE-189, KEYNOTE-021, and KEYNOTE-407 (4,10,12).…”

Section: Introductionmentioning

confidence: 99%

“…We therefore conducted a study to assess prognostic factors in advanced NSCLC patients treated with PD-1 inhibitor plus chemotherapy. Finally, we aimed to develop a nomogram that is a reliable and convenient prognostic tool to quantify risk of progression for cancer patients (14,16,20) to accurately predict PFS.…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Development and Validation of a Nomogram for Predicting Prognosis to Immune Checkpoint Inhibitors Plus Chemotherapy in Patients With Non-Small Cell Lung Cancer

et al. 2021

View full text Add to dashboard Cite

BackgroundImmune checkpoint inhibitors (ICIs) plus chemotherapy improved the prognosis of patients with non-small cell lung cancer (NSCLC); however, reliable prognostic biomarkers are lacking. We explored factors associated with prognosis and developed a predictive model.MethodsWe retrospectively analyzed 130 consecutive stage IIIA–IVB NSCLC patients treated with ICIs combined with chemotherapy. Cox univariate and multivariate proportional hazards regression analyses were used to identify prognostic factors associated with progression-free survival (PFS). A nomogram was developed based on key factors in the training cohort (n = 86) and evaluated in the validation cohort (n = 44). According to the nomogram-based total point scores, we divided patients into low- and high-risk groups.ResultsIn the training cohort, bone metastases (p = 0.017) and an increased derived neutrophil-to-lymphocyte ratio (p = 0.018) were significantly associated with poor PFS, while smoking (p = 0.007) and programmed death-ligand 1 (PD-L1) ≥50% (p = 0.001) were associated with improved PFS. A nomogram based on these factors was developed to predict PFS at 3, 6, and 12 months. The C-index of the nomogram to predict PFS was 0.725 (95% CI: 0.711–0.739) in the training cohort and 0.688 (95% CI: 0.665–0.711) in the validation cohort. The area under the curve (AUC) exhibited an acceptable discriminative ability, and calibration curves demonstrated a consistency between the actual results and predictions. In the training cohort, the median PFS (mPFS) was 12.3 and 5.7 months in the low- and high-risk groups, respectively (p < 0.001). In the validation cohort, the mPFS was 12.6 and 6.2 months in the low- and high-risk groups, respectively (p = 0.021).ConclusionsA predictive nomogram was developed to help clinicians assess prognosis early for advanced NSCLC patients who received ICI plus chemotherapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Data Collectionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Development and Validation of a Nomogram for Predicting Prognosis to Immune Checkpoint Inhibitors Plus Chemotherapy in Patients With Non-Small Cell Lung Cancer

et al. 2021

View full text Add to dashboard Cite

show abstract

Smoking status combined with tumor mutational burden as a prognosis predictor for combination immune checkpoint inhibitor therapy in non‐small cell lung cancer

et al. 2021

View full text Add to dashboard Cite

Background This study aimed to explore the prognostic value of tumor mutational burden (TMB) combined with smoking status in advanced non‐small cell lung cancer (NSCLC) patients who received immune checkpoint inhibitor therapy (anti PD‐1/PD‐L1 therapy) combined with chemotherapy or anti‐angiogenesis therapy. Methods We conducted a retrospective analysis of NSCLC patients who underwent next‐generation sequencing test (either 295‐gene panel NGS or 1021‐gene panel NGS) from September 2017 to November 2020. The relationship between TMB and smoking status was investigated. Kaplan–Meier survival analysis was used to compare progression‐free survival (PFS) of the NSCLC patients who received combination immunotherapy grouped by TMB value and smoking status. Results We enrolled 323 cases and 388 cases of NSCLC patients in the 295‐gene panel cohort and 1021‐gene panel cohort, respectively. Positive correlation between TMB and smoking status was found in lung adenocarcinoma, but not in lung squamous cell carcinoma. Participants with both high TMB and smoking status who received immune checkpoint therapy combined with chemotherapy or anti‐angiogenesis therapy had longer PFS than other participants (p < 0.05). Conclusions The combination of TMB with smoking status might be a potential predictor for the efficacy of combination immunotherapy in advanced NSCLC.

show abstract

Potential therapeutics using tumor-secreted lactate in nonsmall cell lung cancer

Liao

Kempson

Hsieh

et al. 2021

Drug Discovery Today

View full text Add to dashboard Cite

Development of nomograms to predict therapeutic response and prognosis of non-small cell lung cancer patients treated with anti-PD-1 antibody

Cited by 17 publications

References 35 publications

Development and Validation of a Nomogram for Predicting Prognosis to Immune Checkpoint Inhibitors Plus Chemotherapy in Patients With Non-Small Cell Lung Cancer

Development and Validation of a Nomogram for Predicting Prognosis to Immune Checkpoint Inhibitors Plus Chemotherapy in Patients With Non-Small Cell Lung Cancer

Smoking status combined with tumor mutational burden as a prognosis predictor for combination immune checkpoint inhibitor therapy in non‐small cell lung cancer

Potential therapeutics using tumor-secreted lactate in nonsmall cell lung cancer

Contact Info

Product

Resources

About